Global sales for the cervical and lumbar disc replacement devices were $23.4 million, according to a news release. Resources associated with the discs will be allocated to “more profitable growth opportunities.”
Orthofix will still fulfill requirements related to post-market surveillance activities and completion of an Investigational Device Exemption study in the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.